• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic.

作者信息

Dougados Maxime

机构信息

Université de Paris, Department of Rheumatology - Hôpital Cochin. Assistance Publique-Hôpitaux de Paris, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France.

出版信息

Lancet Rheumatol. 2021 Jun;3(6):e395-e396. doi: 10.1016/S2665-9913(21)00077-1. Epub 2021 Mar 25.

DOI:10.1016/S2665-9913(21)00077-1
PMID:33786453
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7993927/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eda/7993927/47b7f43ffd44/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eda/7993927/47b7f43ffd44/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eda/7993927/47b7f43ffd44/fx1_lrg.jpg

相似文献

1
Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic.在2019冠状病毒病大流行期间管理接受利妥昔单抗治疗的风湿性疾病患者。
Lancet Rheumatol. 2021 Jun;3(6):e395-e396. doi: 10.1016/S2665-9913(21)00077-1. Epub 2021 Mar 25.
2
Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020.管理 COVID-19 大流行期间的风湿性疾病患者：法国风湿病学会回答了截至 2020 年 5 月最常被问到的问题。
Joint Bone Spine. 2020 Oct;87(5):431-437. doi: 10.1016/j.jbspin.2020.05.006. Epub 2020 May 27.
3
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.由于 SARS-CoV-2 感染，接受利妥昔单抗治疗的风湿性疾病患者出现严重疾病和死亡的比率较高：一项描述性研究。
Rheumatol Int. 2020 Dec;40(12):2015-2021. doi: 10.1007/s00296-020-04699-x. Epub 2020 Sep 18.
4
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.COVID-19 在接受靶向生物制剂和合成疾病修饰抗风湿药物治疗的成人和儿科风湿性疾病患者队列中的发病率。
Semin Arthritis Rheum. 2020 Aug;50(4):564-570. doi: 10.1016/j.semarthrit.2020.05.001. Epub 2020 May 16.
5
Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.Fcγ受体多态性对接受利妥昔单抗治疗的风湿性疾病患者迟发性中性粒细胞减少症的发生及无疾病活动生存期的影响。
Arthritis Res Ther. 2017 Mar 7;19(1):44. doi: 10.1186/s13075-017-1241-0.
6
Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.COVID-19 对癌症免疫治疗相关风湿并发症患者的影响：一项注册调查研究结果。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001550.
7
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease.利妥昔单抗的使用与患有系统性风湿疾病的COVID-19患者不良临床结局的风险
Rheumatol Int. 2020 Dec;40(12):2117-2118. doi: 10.1007/s00296-020-04715-0. Epub 2020 Oct 12.
8
[A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic].[一项关于炎症性风湿疾病患者在新冠疫情期间免疫抑制药物治疗依从性的横断面研究]
Z Rheumatol. 2020 May;79(4):379-384. doi: 10.1007/s00393-020-00800-8.
9
Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?在 COVID-19 大流行期间及以后，是否可以延长 MS 患者的利妥昔单抗给药间隔？
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 25;7(5). doi: 10.1212/NXI.0000000000000825. Print 2020 Sep.
10
Managing patients with rheumatic conditions during the covid-19 pandemic.在新冠疫情期间管理风湿性疾病患者
BMJ. 2020 Apr 27;369:m1633. doi: 10.1136/bmj.m1633.

引用本文的文献

1
Persistent-relapsing SARS-CoV-2 infection following rituximab treatment for autoimmune rheumatic diseases: diagnosis and outcomes.利妥昔单抗治疗自身免疫性风湿性疾病后持续性复发的严重急性呼吸综合征冠状病毒2感染：诊断与转归
RMD Open. 2025 Jul 21;11(3):e005756. doi: 10.1136/rmdopen-2025-005756.
2
Six month assessment of low dose rituximab in the treatment of rheumatoid arthritis during coronavirus disease 2019 (COVID-19) pandemic.2019冠状病毒病（COVID-19）大流行期间低剂量利妥昔单抗治疗类风湿关节炎的六个月评估
Egypt Rheumatol. 2021 Jun;43(3):253-256. doi: 10.1016/j.ejr.2021.05.001. Epub 2021 May 6.
3
Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugal-A Multicenter, Nationwide Study.

本文引用的文献

1
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.接受利妥昔单抗治疗的炎症性风湿和肌肉骨骼疾病患者的COVID-19结局：一项队列研究。
Lancet Rheumatol. 2021 Jun;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X. Epub 2021 Mar 25.
2
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者 COVID-19 相关死亡的相关因素：来自 COVID-19 全球风湿病联盟医生报告登记处的结果。
Ann Rheum Dis. 2021 Jul;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27.
3
葡萄牙炎症性风湿病患者感染的危险因素、重症疾病预测因素及对 COVID-19 的抗体反应——一项多中心全国性研究
Front Med (Lausanne). 2022 Jun 13;9:901817. doi: 10.3389/fmed.2022.901817. eCollection 2022.
4
A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany.一项评估德国风湿病学家对 COVID-19 疫苗的知识、看法和态度的调查。
Rheumatol Int. 2021 Nov;41(11):1949-1956. doi: 10.1007/s00296-021-04986-1. Epub 2021 Sep 8.
Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients.
COVID-19 严重程度与风湿和炎症性疾病患者的生存：来自法国 RMD COVID-19 队列的 694 例患者的数据。
Ann Rheum Dis. 2021 Apr;80(4):527-538. doi: 10.1136/annrheumdis-2020-218310. Epub 2020 Dec 2.
4
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.SARS-CoV-2 中和抗体 LY-CoV555 治疗门诊新冠患者的疗效。
N Engl J Med. 2021 Jan 21;384(3):229-237. doi: 10.1056/NEJMoa2029849. Epub 2020 Oct 28.
5
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.接受利妥昔单抗治疗的炎症性风湿疾病患者发生重症新型冠状病毒肺炎的风险增加。
Ann Rheum Dis. 2021 May;80(5):e67. doi: 10.1136/annrheumdis-2020-218075. Epub 2020 Jun 26.
6
Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.利妥昔单抗会损害类风湿关节炎患者接种流感疫苗后的免疫球蛋白（Ig）M和IgG（亚类）反应。
Clin Exp Immunol. 2014 Oct;178(1):40-7. doi: 10.1111/cei.12390.
7
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.类风湿关节炎患者应用利妥昔单抗的更新共识声明。
Ann Rheum Dis. 2011 Jun;70(6):909-20. doi: 10.1136/ard.2010.144998. Epub 2011 Mar 6.